Eris Lifesciences Limited shareholders unanimously adopted the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, during the 20th Annual General Meeting held on September 25, 2026. The meeting, conducted via Video Conferencing, also ratified cost auditor remuneration and approved key director reappointments.

Voting results on financial statements

The resolution to receive, consider, and adopt the audited financial statements along with Board and Auditor reports received overwhelming support. Out of 122,287,170 shares voted through remote e-voting, 122,287,168 shares voted in favor, representing 99.997% of valid votes. Only two members cast negative votes totaling 2 shares. No votes were cast during the live e-voting session via Video Conferencing.

Director reappointments and dissent

Shareholders approved the reappointment of Kaushal Kamlesh Shah (DIN: 01229038), who retired by rotation. While promoters voted entirely in favor, public institutions recorded a 2.83% dissent against this ordinary resolution. Overall, 99.26% of total votes polled supported his reappointment.

A Special Resolution for the reappointment of Sujesh Vasudevan (DIN: 08240092) as an Independent Director saw higher opposition. Public institutions voted 8.90% against the resolution, while non-institutional public shareholders registered a negligible 0.0023% dissent. The final consolidated result showed 97.67% in favor and 2.32% against.

Cost auditor remuneration

The ratification of remuneration for Cost Auditors for the Financial Year ending March 31, 2027, was passed with near-unanimous support. Remote e-voting results showed 100% of valid votes in favor, with only three members casting a combined 26 shares against the resolution.

Governance and compliance details

The proceedings were conducted in compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The scrutinizer’s report was submitted by Ravi Kapoor & Associates, confirming that no invalid or incomplete votes were found in the e-voting system. The remote e-voting period remained open from September 22, 2026, to September 24, 2026.

Milind Talegaonkar, Company Secretary and Compliance Officer, signed the proceedings digitally on September 25, 2026. The Annual General Meeting commenced at 11:00 am and concluded at 11:30 am.

Eris Lifesciences has appointed Akhil Awasthi as an additional non-executive, independent director. The appointment is effective from September 26, 2026.

The Board of Directors approved the move on September 21, 2026, based on the recommendation of the Nomination and Remuneration Committee. The decision was formalized through a circular resolution issued the same day.

Appointment Details

Mr. Awasthi will serve a term of five years. His appointment as an Additional Director is subject to the approval of the company’s members at a general meeting.

Profile and Governance

Mr. Awasthi brings over three decades of experience in private equity, investment management, healthcare, and corporate governance. He previously served as Founding Managing Partner and Investment Committee Member of Tata Capital Growth Fund. He also held the position of Partner at Baring Private Equity Partners (India) Ltd.

The filing confirms that Mr. Awasthi is not related to any existing director of the company. He is not debarred from holding the office of Director by SEBI or any other authority. The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.